Artoss, Inc. is pleased to announce the successful completion of its recent funding round of Unsecured Convertible Notes. The round, which began in 2017 with a target of raising $500,000, was oversubscribed to twice that amount or a total of $1 million.
James J. Cassidy, Ph.D., Managing Director of Artoss, Inc., the exclusive North American distributors for NanoBone® Bone Graft in orthopaedic surgery, said, “We have been overwhelmed by the interest shown in our second round of angel funding. We are especially grateful to those investors who participated in our 2016 funding round and chose to increase their investment in this round as well as to our new investors for their support of Artoss.”
Paul Byerley, Managing Director of Artoss, Inc. said, “We are very pleased with our commercial success to-date and appreciate the support of our investors. Surgeon feedback on the clinical performance of NanoBone SBX Putty and QDremains extremely positive. We look forward to expanding our distribution network to put our superior bone grafting solution in the hands of more surgeons.”.
Artoss, Inc. is using the proceeds of this funding to support the development of additional NanoBone Bone Graft products for the US market, for costs associated with regulatory requirements, and for commercialization activities.
For further information, please contact:
425 E Saint Germain St., Suite 106
Saint Cloud, MN 56304-0752